Phase Advance

Phase Advance, Inc. is a US-based company specializing in advanced predictive analytics for drug development, utilizing proprietary mathematical models to enhance clinical outcomes for pharmaceutical and biotechnology firms. Phase Advance, Inc. , founded in 2024 and headquartered in Dallas, US, focuses on predictive analytics in drug development.

The company has been involved in one deal as of October 16, 2025, attracting venture funding from QNova Capital. The founder's previous ventures are not documented, but this initiative marks a significant step in their career. Phase Advance AI specializes in advanced predictive analytics for drug development, leveraging proprietary mathematical models developed over decades. Their core offering predicts individual-patient clinical response rates, identifies optimal biomarkers, determines effective dosages, and assesses drug performance relative to other candidates.

This capability is vital during the preclinical stage of drug development, enabling clients to streamline their research and enhance the likelihood of successful clinical outcomes. The company serves pharmaceutical and biotechnology firms across North America, Europe, and Asia, providing reliable forecasting tools for improved drug development strategies. Phase Advance AI’s revenue model is primarily based on B2B partnerships with clients in the pharmaceutical and biotechnology sectors. Revenue is generated through subscription-based access to their advanced predictive analytics platform, which offers tailored insights for informed decision-making in drug development.

Additionally, Phase Advance engages in collaborative agreements for clients to access their technology on a contractual basis, ensuring ongoing support and updates. The pricing reflects the sophisticated nature of their offerings, accommodating specific client needs. In October 2025, Phase Advance, Inc. raised an undisclosed amount of venture funding from QNova Capital, which will be utilized to accelerate AI-driven drug development and reduce reliance on animal models in regulatory processes.

The company plans to design and launch new products aimed at enhancing their predictive capabilities, with targeted expansion into additional markets in North America and Europe by the end of 2026.